Budesonide Oral Suspension (Eohilia) Drug Interaction Analysis

Budesonide Oral Suspension (Eohilia) is a steroid drug and some interactions may occur when used with other drugs. Budesonide is a substrate ofCYP3A4, which means that its metabolism and clearance are mainly dependent on the CYP3A4 enzyme. Therefore, any drug that affects CYP3A4 enzyme activity may affect the metabolism of budesonide, thereby affecting its therapeutic efficacy and safety.

Special attention is required when coadministering budesonide withCYP3A4 inhibitors, as these inhibitors will inhibit the metabolism of budesonide, leading to an increase in the concentration of budesonide in the body, thus increasing the risk of systemic side effects. Common CYP3A4 inhibitors include ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, cyclosporine, etc. When these drugs are used together with budesonide, the plasma concentration of budesonide may significantly increase, increasing the probability of side effects, especially common side effects of steroid drugs, such as weight gain, edema, hyperglycemia, gastrointestinal discomfort, etc.

Grapefruit juice is also a known inhibitor of CYP3A4 and can significantly increase budesonide plasma concentrations, especially at higher concentrations. Therefore, patients with esophagitis should avoid drinking grapefruit juice while taking budesonide to avoid potential side effects caused by increased drug concentration.

ExceptCYP3A4 inhibitors, some drugs may interact with budesonide, affecting its efficacy or causing other adverse reactions. For example, when budesonide is used in combination with certain antibiotics or antifungal drugs, it may also cause changes in the drug absorption rate or metabolism, thereby affecting the effectiveness of budesonide.

In short, the combined use of budesonide oral suspension andCYP3A4 inhibitors may lead to a significant increase in the plasma concentration of budesonide and increase the risk of side effects. Therefore, when using budesonide, patients should fully discuss possible drug interactions with their doctors and adjust their medication regimen as needed to ensure safe and effective treatment.

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213976s000lbl.pdf